[Market Focus] Genomictree Rises on Confirmation of Expert Committee Meeting for EarlyTect-B Approval by MFDS

Genomictree shares are showing strong performance. This appears to be influenced by news that the Ministry of Food and Drug Safety has finalized plans to hold an expert committee meeting on November 6 regarding the manufacturing approval review for Genomictree's bladder cancer in vitro diagnostic test, 'EarlyTect-B'.

As of 1:56 p.m. on November 4, Genomictree is trading at 25,200 won, up 13.77% from the previous day.

A Genomictree representative stated, "The confirmation of this schedule is the result of the Ministry of Food and Drug Safety actively working to expedite the review process by managing this case as a 'top-priority civil petition.' Despite initial difficulties in coordinating the schedule, the meeting date was set quickly."

The company added, "The Ministry of Food and Drug Safety has already completed most of the key document reviews, and with this upcoming expert committee meeting, we expect the approval review process to enter its final stage."

This content was produced with the assistance of AI translation services.